Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Urgent PC.
- Who it may be relevant to
- Registry conditions: Overactive Bladder, Overactive Bladder Syndrome. Basic parameters: 5 years — 21 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to find out if overactive bladder (OAB) can be safely treated by stimulating a nerve near the ankle. This procedure is called percutaneous tibial nerve stimulation (PTNS). It will be done by a device called the Urgent PC. The Urgent PC works by sending weak electrical signals through a thin needle to the nerve near the ankle. Stimulating this nerve may change bladder control.
Detailed description
This study is a single-arm, open label, prospective, multicenter study of 50 participants aged 5-21 years with OAB. Participants will undergo outpatient PTNS sessions per routine clinical care using Urgent PC once weekly for 12 weeks. Patients, parents and clinicians will not be blinded to treatment or assessments during the study.
Interventions
- Device Urgent PC
PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
Primary outcome measures
- The frequency of select safety Events of Special Interest. [Time frame: Weekly, Week 1 through Week 16]
- Change in maximum voided volume on the Bladder Diary [Time frame: Week 1, Week 12]
Secondary outcome measures (5)
- Proportion of children who experienced complete response, no response, or partial response on the Vancouver Dysfunctional Elimination Survey (VDES) [Time frame: Screening, Weekly (Week 1 through Week 12)]
- Change in OAB symptoms (Urgency, Frequency and Daytime Incontinence) reported on the VDES [Time frame: Screening, Weekly (Week 1 through Week 12), Week 16, Week 36]
- Proportion of children who develop a febrile UTI [Time frame: Weekly, Week 1 through Week 12]
- The change of Pediatric Incontinence Quality of Life (PINQ) score [Time frame: Week 1, Week 6, Week 12, Week 16, and Week 36]
- The percent of study visits attended within the protocol specified window from baseline through Week 12 [Time frame: Screening, Weekly (week 1 through week 12)]
Eligibility criteria
Inclusion criteria
- Age 5-21 years old (inclusive)
- Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization from the participant or the participant's parent/legal guardian/legally authorized representative (LAR)
- Minor participant is willing and able to provide assent (as applicable)
- History of primary or secondary non-neurogenic OAB as defined by a VDES score of ≥11 and a positive modified bother score within 30 days of consent
- Has previously tried and failed standard urotherapy and at least one anticholinergic or beta-3 adrenergic agonist
- Adequate fluid intake for age as reported by participant or parent/legal guardian/LAR
- Micturition frequency of at least 8 times (mean)/day for at least 4 weeks prior to enrollment
- At least 1 daytime incontinence episode (mean)/day for at least 4 weeks prior to enrollment
- If on allowed treatment for OAB, stable dose for at least 30 days prior to screening and willingness to continue that dose for the duration of the study
Exclusion criteria
- Known or apparent untreated anatomical abnormality of the lower urinary tract (e.g., untreated ureterocele)
- Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)
- Presence of local skin lesions (e.g., rash, skin infections) on the medial surfaces of both ankles at the time of consent
- Metal implants in the medial ankle area
- Pacemakers or implantable defibrillators
- History of excessive bleeding
- Nerve damage that may impact the percutaneous tibial nerve or pelvic floor function
- History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)
- Known current, untreated UTI
- Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential
- Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety
- Previous treatment with this device or participation in this study or in any other study for the treatment of OAB
- High-grade vesicoureteral reflux (grades 4-5)
- Diagnosed diabetes insipidus (pituitary, nephrogenic, or acquired)
- Stage 4-5 chronic kidney disease (CKD) (since device may further disrupt or exacerbate abnormal urine flow)
- Significant post-void residual defined as >60 mL
- Initiation of or change of OAB treatment during screening or the duration of the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06769854 · Pro00114395 · HHSN275201800003I